Touchstone Plays Tough As IP Group Ups Bid To £490m
One of the key attractions is Touchstone's holdings in Imperial College spin-offs such as Cell Medica, Circassia Pharmaceuticals and TopiVert Pharma.
You may also be interested in...
Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.
Circassia has thrown in the towel on investing in anti-allergy vaccines and will focus now on respiratory activities, after its house dust mite allergy study missed its primary endpoints.
Cell Medica has just raised a large Series C from UK institutional investors to explore the use of novel cell-based immunotherapies in solid tumors, a “new chapter” for this class of therapeutic agents.